دورية أكاديمية
Harnessing RIG-I and intrinsic immunity in the tumor microenvironment for therapeutic cancer treatment.
| العنوان: | Harnessing RIG-I and intrinsic immunity in the tumor microenvironment for therapeutic cancer treatment. |
|---|---|
| المؤلفون: | Elion DL; Cancer Biology Program, Vanderbilt University School of Medicine, Nashville, TN 37232, USA., Cook RS; Department of Cell and Developmental Biology, Vanderbilt University School of Medicine, Nashville, TN 37232, USA.; Department of Biomedical Engineering, Vanderbilt University School of Engineering, Nashville, TN 37232, USA.; Vanderbilt Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN 37232, USA. |
| المصدر: | Oncotarget [Oncotarget] 2018 Jun 22; Vol. 9 (48), pp. 29007-29017. Date of Electronic Publication: 2018 Jun 22 (Print Publication: 2018). |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Impact Journals Country of Publication: United States NLM ID: 101532965 Publication Model: eCollection Cited Medium: Internet ISSN: 1949-2553 (Electronic) Linking ISSN: 19492553 NLM ISO Abbreviation: Oncotarget Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: Albany, N.Y. : Impact Journals |
| مستخلص: | Cancer immunotherapies that remove checkpoint restraints on adaptive immunity are gaining clinical momentum. Approaches aimed at intrinsic cellular immunity in the tumor microenvironment are less understood, but are of intense interest, based on their ability to induce tumor cell apoptosis while orchestrating innate and adaptive immune responses against tumor antigens. The intrinsic immune response is initiated by ancient, highly conserved intracellular proteins that detect viral infection. For example, the RIG-I-like receptors (RLRs), a family of related RNA helicases, detect viral oligonucleotide patterns of certain RNA viruses. RLR activation induces immunogenic cell death of virally infected cells, accompanied by increased inflammatory cytokine production, antigen presentation, and antigen-directed immunity against virus antigens. Approaches aimed at non-infectious RIG-I activation in cancers are being tested as a treatment option, with the goal of inducing immunogenic tumor cell death, stimulating production of pro-inflammatory cytokines, enhancing tumor neoantigen presentation, and potently increasing cytotoxic activity of tumor infiltrating lymphocytes. These studies are finding success in several pre-clinical models, and are entering early phases of clinical trial. Here, we review pre-clinical studies of RLR agonists, including the successes and challenges currently faced RLR agonists on the path to clinical translation. Competing Interests: CONFLICTS OF INTEREST The authors declare no conflicts of interest with the materials described herein. |
| References: | Clin Cancer Res. 2012 Dec 1;18(23):6497-508. (PMID: 23032745) Cell Death Differ. 2014 Dec;21(12):1825-37. (PMID: 25012502) Clin Cancer Res. 2015 Jan 15;21(2):286-94. (PMID: 25424847) J Immunol. 2007 May 15;178(10):6444-55. (PMID: 17475874) Genomics. 2001 Dec;78(3):129-34. (PMID: 11735219) Aging Clin Exp Res. 2016 Feb;28(1):69-76. (PMID: 25986237) Adv Cancer Res. 2001;83:117-58. (PMID: 11665717) Cancer Res. 2016 Apr 15;76(8):2137-52. (PMID: 26951929) Cell. 2014 Oct 23;159(3):499-513. (PMID: 25417103) J Clin Invest. 2009 Aug;119(8):2399-411. (PMID: 19620789) Viral Immunol. 2017 Jul/Aug;30(6):408-420. (PMID: 28609250) J Immunother Cancer. 2017 Nov 21;5(1):92. (PMID: 29157306) Adv Immunol. 2000;74:181-273. (PMID: 10605607) Pharmacol Ther. 2009 Nov;124(2):219-34. (PMID: 19615405) Sci Rep. 2015 Oct 09;5:14991. (PMID: 26450567) Clin Cancer Res. 2010 Apr 15;16(8):2443-9. (PMID: 20371685) Oncogene. 2003 May 22;22(21):3307-18. (PMID: 12761501) Nat Biotechnol. 2006 May;24(5):559-65. (PMID: 16648842) Cancer Res. 2013 Mar 15;73(6):1709-20. (PMID: 23338611) Vaccine. 2006 Jun 12;24(24):5119-32. (PMID: 16704888) Int J Cancer. 2009 May 15;124(10):2478-87. (PMID: 19173282) Curr Biol. 2010 Apr 13;20(7):R328-33. (PMID: 20392426) Immunity. 2009 Jul 17;31(1):25-34. (PMID: 19576794) Cancer Immunol Res. 2013 Nov;1(5):340-50. (PMID: 24777970) PLoS One. 2009 Jun 01;4(6):e5760. (PMID: 19484123) Annu Rev Med. 2017 Jan 14;68:297-315. (PMID: 27813875) J Immunol. 2005 Sep 1;175(5):2851-8. (PMID: 16116171) J Immunol. 2005 Oct 15;175(8):5260-8. (PMID: 16210631) Oncotarget. 2015 Oct 6;6(30):29664-74. (PMID: 26336994) Science. 2006 Nov 10;314(5801):997-1001. (PMID: 17038589) Clin Lung Cancer. 2017 Sep;18(5):444-459.e1. (PMID: 28416123) Nat Immunol. 2005 Oct;6(10):981-8. (PMID: 16127453) Nature. 2009 Oct 8;461(7265):788-92. (PMID: 19776740) Sci Transl Med. 2015 Apr 15;7(283):283ra52. (PMID: 25877890) Curr Biol. 2002 May 14;12(10):838-43. (PMID: 12015121) Cell. 2010 Mar 19;140(6):805-20. (PMID: 20303872) Bioconjug Chem. 2018 Mar 21;29(3):742-747. (PMID: 29350913) Breast. 2016 Oct;29:241-50. (PMID: 27481651) J Transl Med. 2007 Feb 12;5:10. (PMID: 17295916) J Virol. 2011 Feb;85(3):1224-36. (PMID: 21084468) Immunity. 2013 Jul 25;39(1):27-37. (PMID: 23890061) J Immunol. 2008 Feb 1;180(3):1749-57. (PMID: 18209072) J Leukoc Biol. 2001 Jun;69(6):912-20. (PMID: 11404376) Nat Immunol. 2004 Jul;5(7):730-7. (PMID: 15208624) Oncogene. 2018 Apr;37(15):2037-2051. (PMID: 29367762) Science. 2006 Nov 10;314(5801):994-7. (PMID: 17038590) Leuk Res. 2017 Jul;58:23-30. (PMID: 28380403) Adv Exp Med Biol. 2017;1024:175-194. (PMID: 28921470) Nat Med. 2008 Nov;14(11):1256-63. (PMID: 18978796) Cell Host Microbe. 2008 Sep 11;4(3):198-208. (PMID: 18779046) Nat Rev Cancer. 2012 Mar 22;12(4):252-64. (PMID: 22437870) Immunity. 2011 May 27;34(5):680-92. (PMID: 21616437) J Clin Invest. 2015 Sep;125(9):3347-55. (PMID: 26325032) Proc Natl Acad Sci U S A. 2015 Dec 15;112(50):15408-13. (PMID: 26607445) N Engl J Med. 2010 Aug 19;363(8):711-23. (PMID: 20525992) Amino Acids. 2010 May;38(5):1283-99. (PMID: 19882216) Neurosurgery. 1996 Jun;38(6):1096-103; discussion 1103-4. (PMID: 8727138) Proc Natl Acad Sci U S A. 2008 Oct 28;105(43):16743-8. (PMID: 18948594) Nature. 2007 Apr 19;446(7138):916-920. (PMID: 17392790) Cancer Epidemiol Biomarkers Prev. 2014 Dec;23(12):2965-70. (PMID: 25392179) Sci Rep. 2016 Jan 12;6:19049. (PMID: 26754564) Cell Rep. 2016 Jan 12;14(2):282-97. (PMID: 26748708) Curr Opin Struct Biol. 2008 Apr;18(2):236-42. (PMID: 18206362) EMBO J. 2008 Aug 6;27(15):2147-57. (PMID: 18636090) Nucleic Acids Res. 2000 Jan 1;28(1):333-4. (PMID: 10592265) Nat Immunol. 2010 Jan;11(1):63-9. (PMID: 19915568) Nature. 2008 Oct 2;455(7213):674-8. (PMID: 18724357) EMBO J. 2005 Dec 7;24(23):4018-28. (PMID: 16281057) Proc Natl Acad Sci U S A. 2007 Jan 9;104(2):582-7. (PMID: 17190814) Cell Death Differ. 2018 Mar;25(3):486-541. (PMID: 29362479) J Virol. 2006 Dec;80(24):12332-42. (PMID: 17020950) Sci Adv. 2018 Feb 21;4(2):e1701854. (PMID: 29492454) Lancet Oncol. 2009 May;10(5):459-66. (PMID: 19269895) Stem Cells. 2013 Jun;31(6):1064-74. (PMID: 23390110) J Med Virol. 2017 Sep;89(9):1620-1628. (PMID: 28303593) Mol Ther. 2013 Jun;21(6):1169-81. (PMID: 23568258) Cell. 2005 Sep 9;122(5):669-82. (PMID: 16125763) Oncotarget. 2016 May 3;7(18):26496-515. (PMID: 27034163) Clin Cancer Res. 2014 Mar 1;20(5):1355-65. (PMID: 24520093) Proc Natl Acad Sci U S A. 2002 Jan 22;99(2):637-42. (PMID: 11805321) Neuro Oncol. 2010 Oct;12(10):1071-7. (PMID: 20615924) J Biol Chem. 2009 Jan 9;284(2):807-17. (PMID: 19017631) J Interferon Cytokine Res. 2003 Dec;23(12):745-56. (PMID: 14769151) J Hematol Oncol. 2017 Apr 7;10(1):82. (PMID: 28388966) Nature. 2014 Oct 16;514(7522):372-375. (PMID: 25119032) Cancer Immunol Res. 2014 Sep;2(9):901-10. (PMID: 24913717) Cancer Res. 2010 Jul 1;70(13):5293-304. (PMID: 20551064) Cancer Cell. 2014 Jan 13;25(1):49-63. (PMID: 24360797) Mol Ther. 2016 Feb;24(1):135-45. (PMID: 26548591) Cytokine Growth Factor Rev. 2016 Jun;29:101-7. (PMID: 26993858) Nature. 2005 Oct 20;437(7062):1167-72. (PMID: 16177806) Nucleic Acids Res. 1993 Feb 11;21(3):751-2. (PMID: 8382805) Curr Opin Virol. 2011 Sep;1(3):167-76. (PMID: 21949557) J Exp Med. 2010 Sep 27;207(10):2053-63. (PMID: 20837696) J Biol Chem. 2002 Oct 4;277(40):37029-36. (PMID: 12133833) |
| معلومات مُعتمدة: | P30 CA068485 United States CA NCI NIH HHS; P50 CA098131 United States CA NCI NIH HHS; R25 GM062459 United States GM NIGMS NIH HHS; UL1 TR000445 United States TR NCATS NIH HHS |
| فهرسة مساهمة: | Keywords: RIG-I; immunotherapy; innate immunity; pyroptosis; tumor microenvironment |
| تواريخ الأحداث: | Date Created: 20180711 Latest Revision: 20191120 |
| رمز التحديث: | 20221213 |
| مُعرف محوري في PubMed: | PMC6034747 |
| DOI: | 10.18632/oncotarget.25626 |
| PMID: | 29989043 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1949-2553 |
|---|---|
| DOI: | 10.18632/oncotarget.25626 |